Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
2023-07-31 10:51:57 ET Daiichi Sankyo press release ( OTCPK:DSKYF ): Q1 GAAP EPS of ¥29.72. Revenue of ¥350.84B (+25.2% Y/Y). For further details see: Daiichi Sankyo GAAP EPS of ¥29.72, revenue of ¥350.84B
2023-07-13 11:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Japan drove internatio...
2023-07-12 07:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Japan drove internatio...
2023-05-26 03:13:14 ET Summary Daiichi Sankyo is leading the world in the development of antibody-drug conjugates, which are finally paying off in cancer after more than a decade of ups and downs. The company stands poised to continue to stretch its arms in the space and reap sign...
2023-05-01 15:40:06 ET Daiichi Sankyo Company, Limited (DSKYF) Q4 2022 Results Conference Call April 27, 2023 04:30 AM ET Company Participants Hiroyuki Okuzawa - Head, Corporate Planning and Management Division, CFO Ken Takeshita - Global Head of Research and Develop...
2023-04-27 10:16:50 ET Daiichi Sankyo Co. ( OTCPK:DSKYF ): FY GAAP EPS of ¥56.91. Revenue of ¥1.28T. For further details see: Daiichi Sankyo Co. GAAP EPS of ¥56.91, revenue of ¥1.28T
2023-04-21 11:32:43 ET The US FDA has extended by three months its review of Daiichi Sankyo's ( OTCPK:DSKYF ) NDA for quizartinib for newly diagnosed acute myeloid leukemia (AML). The new agency action date is July 24. The reason for the extra time is that the agency needs...
2023-04-20 12:12:30 ET Summary BMEZ launched right before Covid, riding up the boost when speculative growth took off. In 2022, the story was much different, and the fund struggled significantly. This fund is much riskier than its older sister fund, BME, but it also can provid...
2023-03-16 09:07:22 ET Esperion Therapeutics ( NASDAQ: ESPR ) continued the post-market selloff on Thursday due to a payment dispute with Daiichi Sankyo ( OTCPK:DSNKY ) over its cholesterol-lowering agent bempedoic acid, prompting Bank of America to downgrade the stock. ...
Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...